Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 ARROS-1 trial of zidesamtinib in previously ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...

Returning to Boston for its 13 th edition, the IMPACCT Real-World Evidence Summit remains the go-to meeting for RWE experts ...

One-year results from the company's FORWARD-101 trial of islet cell therapy zimislecel (also known as VX-880) showed that all ...

Medistry’s role is that of the registry operator of the .med zone on the World Wide Web. Medistry permits authorised domain ...

In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...

Louisiana Senator Bill Cassidy, who chairs the Senate Health, Education, Labor, & Pensions (HELP) Committee, has called for ...

Around half of people diagnosed with pancreatic cancer will have been diagnosed with diabetes recently, according to NHS ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

The FDA has launched a review of clinical trials that plan to send American citizens' living cells to 'hostile' countries – ...